NZYPTIS Trademark

Trademark Overview


On Monday, July 20, 2020, a trademark application was filed for NZYPTIS with the United States Patent and Trademark Office. The USPTO has given the NZYPTIS trademark a serial number of 90062736. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 6, 2023. This trademark is owned by Eli Lilly and Company. The NZYPTIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
nzyptis

General Information


Serial Number90062736
Word MarkNZYPTIS
Filing DateMonday, July 20, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 6, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 8, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, August 18, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, March 6, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 6, 2023ABANDONMENT - NO USE STATEMENT FILED
Friday, July 15, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 13, 2022SOU EXTENSION 3 GRANTED
Wednesday, July 13, 2022SOU EXTENSION 3 FILED
Wednesday, July 13, 2022TEAS EXTENSION RECEIVED
Thursday, January 20, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 19, 2022SOU EXTENSION 2 GRANTED
Monday, January 10, 2022SOU EXTENSION 2 FILED
Wednesday, January 19, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, January 10, 2022TEAS EXTENSION RECEIVED
Saturday, July 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 1, 2021SOU EXTENSION 1 GRANTED
Thursday, July 1, 2021SOU EXTENSION 1 FILED
Thursday, July 1, 2021TEAS EXTENSION RECEIVED
Tuesday, February 2, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 8, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 8, 2020PUBLISHED FOR OPPOSITION
Wednesday, November 18, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, November 5, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, November 3, 2020ASSIGNED TO EXAMINER
Tuesday, August 18, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 23, 2020NEW APPLICATION ENTERED